Canadian Clinical Trials Group
2016 Spring Meeting of Participants

GYNECOLOGY

DISEASE SITE COMMITTEE MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON
ROOM: CHURCHILL B
SATURDAY APRIL 30, 2016 – 9:00 A.M. - 3:30 P.M.
CHAIRS: MICHAEL FUNG KEE FUNG AND HAL HIRTE

(3:30 P.M. – 4:15 P.M. EXECUTIVE COMMITTEE MEETING – ROOM: STEVENSON - CLOSED)

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
To provide an update of ongoing and recently completed trials and an understanding for the rationale for studies that are proposed or in the process of being activated.

To provide an understanding of principles of immunotherapy and how they could be applied therapeutically to gynecologic malignancies

To provide a framework for the role of tumour sequencing in the design and conduct of clinical trials in the era of personalized medicine.

To understand the role of lay representatives in the development and execution of clinical trials.

9:00 a.m. Opening Remarks and Outline of the Meeting M. Fung-Kee-Fung / H. Hirte

1. Review of minutes and follow-up items from Spring Meeting 2015
2. Introduction of New Lay Representatives – Martina Wood, Leslie Schroeder
3. Overview of Gyne Trials Landscape and update on ecosystem blueprint/roadmap and Strategic Plan for the Gynecologic Disease Site Committee and overview of Gyne DSC submission for CCTG grant renewal

9:30 a.m. Clinical Trial Updates

1. CX.5 / SHAPE (15 min) – lessons learned M. Plante
2. IND.221 (15 min) H. Hirte
3. OV.23 – review of decision not to proceed (10 min) A. Oza
4. Completed studies – OV.21 (10 min) H. MacKay

10:30 a.m BREAK
10:45 a.m  Planned/Proposed Trials for Presentation and Feedback

1. OV.24  
   S. L'Heureux /A. Oza
2. NRG GY004  
   H. MacKay
3. NRG GY005  
   D. Provencher
4. CoNteSSa neoadjuvant cervix trial  
   M. Plante
5. Cabozantinib in Endometrial Ca proposal  
   A. Oza
6. Triapine in cervical cancer  
   Doll/Plante
7. Genome-based classification of ovarian and endometrial cancer: What’s ready for primetime?
   D. Huntsman

12:00 p.m.  LUNCH

1:30 p.m.  Educational Session

Session 1: Basic Science/Translational  
30 minutes
Opportunities for Immunotherapy in gynecologic malignancies  
Pam Ohashi

Session 2: Clinical  
30 minutes
What have we learned from immunotherapy trials in gynecologic malignancies to date: Implications for patient selection and the design of future trials.  
Marcus Butler

2:30 p.m.  Working Group Updates (including overview of trials landscape in disease sites)

1. Ovary (10 min)  
   D. Provencher/H. MacKay
2. Cervix (10 min)  
   M. Plante/C. Doll
3. Endometrium (10 min)  
   M. Bernardini/S. Welch
4. Correlative Sciences and Tumour Biology (10 min)  
   A. Mes-Masson/M. Butler

3:10 p.m.  Other Updates

1. Lay Rep Report – Patient Survey results  
   H. Hirte/M. Fung Kee Fung
2. Other Gyne DSC Rep Reports
3. Report on PMH Phase II Consortium (10 min)  
   A. Oza
4. NCI US – GCSC and Ovarian Cancer Task Force (posted on CCTG website)  
   H. Hirte/M. Fung Kee Fung
5. GCIG Updates (posted on CCTG website)  
   H. Hirte/M. Fung Kee Fung
6. Other  
   All

3:30 p.m.  ADJOURN

Closed meeting of Gyne Executive Council to follow in the Stevenson Room.